journal
MENU ▼
Read by QxMD icon Read
search

Asia-Pacific Journal of Clinical Oncology

journal
https://www.readbyqxmd.com/read/28078806/prognostic-factors-of-hepatocellular-carcinoma-patients-with-portal-vein-tumor-thrombosis-treated-with-transcatheter-arterial-chemoembolization
#1
Hongyuan Liang, Peng Cui, Qiyong Guo, Xiaonan Mao, Feng Wen, Wei Sun, Ming Shan, Zaiming Lu
AIM: To investigate the factors that influence survival of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) following transarterial chemoembolization (TACE). METHODS: Retrospectively enrolled HCC patients with PVTT (n = 57). Patients received TACE, and the local tumor response was evaluated by modified response evaluation criteria in solid tumor (mRECIST). Overall survival and disease progression were evaluated using Kaplan-Meier survival curves...
January 12, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28029222/role-of-adjuvant-chemotherapy-in-t2n0m0-periampullary-cancers
#2
Vikas Ostwal, Caleb Harris, Bhawna Sirohi, Mahesh Goel, Munita Bal, Sadhana Kannan, Shailesh V Shrikhande
AIMS: Surgery is the only modality that offers cure for periampullary adenocarcinoma. However, surgery alone results in failure in 60% of patients. Studies have shown some benefits of chemotherapy in node positive and higher tumor stage patients. We sought to determine the role of adjuvant chemotherapy in early tumors with uninvolved nodes. METHODS: A retrospective analysis of a prospectively maintained database of patients resected of periampullary tumors from 2007 to 2014 was performed...
December 28, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28028915/apatinib-in-gastric-carcinoma-a-case-report-of-partial-response-for-first-line-treatment-in-advanced-disease
#3
Yaping Wang, Minghong Bi, Haoran Zhang, Zhenyuan Gao, Hairong Zhou, Shu Chang
Gastric cancer (GC) is the most common gastrointestinal malignant tumor, with a gradual increasing incidence throughout the world. Mostly GC is diagnosed in its late stage. To date, there is no usable standardized treatment regimen for patients with advanced GC. Apatinib mesylate, small-molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor (TKI), has been approved as third-line treatment for patients with advanced gastric adenocarcinoma in China, October, 2014. Till now, there is no case report about apatinib as first-line treatment for patients with advanced GC in literature...
December 28, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28008715/human-epidermal-growth-factor-receptor-2-status-of-gastric-cancer-patients-in-asia-results-from-a-large-multicountry-study
#4
Nirmala Pathmanathan, Jing-Shu Geng, Wencai Li, Xiu Nie, Januario Veloso, John Wang, Julie Hill, Philip Mccloud, Michael Bilous
AIM: Current estimates of the human epidermal growth factor receptor 2 (HER2)-positivity rate in gastric cancer vary widely in the literature, and there are limited data from countries in Asia. The primary aim of this study was to conduct a clinical audit of laboratories across seven countries in Asia to determine the incidence of HER2-positive gastric cancer in this region. METHODS: Pathologists were asked to collect data on patient gender, age, cancer site, specimen type, tumor spread, type and grade, HER2 test results, including protein and/or gene copy enumeration, and final HER2 status on consecutive gastric cancer cases tested for HER2 in their laboratory over a 2-year period...
December 23, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28004883/afatinib-successfully-treated-leptomeningeal-metastasis-during-erlotinib-treatment-in-a-patient-with-egfr-mutant-exon18-g719s-lung-adenocarcinoma-as-a-second-line-chemotherapy
#5
Motohiro Tamiya, Takayuki Shiroyama, Takashi Nishihara, Takuji Nishida, Manabu Hayama, Ayako Tanaka, Naoko Morishita, Hidekazu Suzuki, Norio Okamoto, Tomonori Hirashima
Exon18 mutations are detected in 3.6% of epidermal growth factor receptor mutations. Exon 18 mutations as driver mutations have higher sensitivities in vitro to second-generation (G)-tyrosine kinase inhibitors (TKIs) than to first G- and third G-TKIs at clinically relevant doses. In clinical trial, first G-TKIs have moderate but insufficient efficacy, and afatinib was more active in uncommon epidermal growth factor receptor mutations. Here, we present a case of a woman who was initially prescribed erlotinib for lung adenocarcinoma with an exon18 mutation...
December 22, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28004882/the-current-practice-preparedness-and-educational-preparation-of-oncology-professionals-to-provide-spiritual-care
#6
Ganessan Kichenadasse, Linda Sweet, Ann Harrington, Shahid Ullah
AIM: Limited data are available on how spiritual needs of patients with cancer care are addressed by Australian oncologists. The objectives of this study were to explore the current practice, preparedness and education of Australian oncologists and oncology trainees on the provision of spiritual care for their patients with cancer. METHODS: Participants were recruited through oncology professional organizations and data collected through an anonymous online survey using a validated questionnaire...
December 22, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28004881/efficacy-and-toxicity-of-pacebom-chemotherapy-in-relapsed-refractory-aggressive-lymphoma-in-the-rituximab-era
#7
Babak Tamjid, Joseph Mckendrick, Anthony Schwarer, Rowan Doig, Philip James, Patrick Hosking, Eliza A Hawkes
AIM: Relapsed/refractory (R/R) aggressive lymphoma outcomes are poor. There is no standard treatment. PACEBOM (prednisolone, doxorubicin, cyclophosphamide, etoposide, bleomycin, vincristine and methotrexate) has shown efficacy for several lymphoma subtypes in published reports. We evaluate PACEBOM+/-rituximab for R/R aggressive lymphomas in this millennium. METHODS: In this retrospective, single-center study, R/R aggressive lymphoma patients who received PACEBOM or its derivatives were identified from the pharmacy database...
December 22, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28004526/exercise-therapy-in-oncology-rehabilitation-in-australia-a-mixed-methods-study
#8
Amy M Dennett, Casey L Peiris, Nora Shields, Delwyn Morgan, Nicholas F Taylor
AIM: Oncology rehabilitation improves outcomes for cancer survivors but little is known about program availability in Australia. The aims of this study were: to describe oncology rehabilitation programs in Australia: determine whether the exercise component of programs is consistent with guidelines: and to explore barriers and facilitators to program implementation. METHODS: A sequential, explanatory mixed-methods study was completed in two phases: (1) a survey of Australian oncology rehabilitation programs; and (2) purposively sampled follow-up semistructured interviews with senior clinicians working in oncology rehabilitation who were involved with exercise prescription...
December 22, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28004512/a-rapid-access-clinic-to-improve-delivery-of-ambulatory-care-to-cancer-patients
#9
James C Kuo, Madhawa De Silva, Chandra Diwakarla, Desmond Yip
BACKGROUND: Cancer patients may find it challenging to access timely advice and care. We evaluated the improvement in delivering ambulatory care in establishing a Rapid Assessment Clinic (RAC) in a cancer center. METHODS: Patients receiving chemotherapy who presented for assessment at the RAC from September 2013 to June 2014 were included for review. Patient demographics, tumor characteristics, presenting complaints, time to assessment, total time spent at the RAC and assessment outcome were extracted...
December 22, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27981760/infliximab-for-ipilimumab-induced-colitis-a-series-of-13-patients
#10
Nadine T Hillock, Sharryn Heard, Ganessan Kichenadasse, Catherine L Hill, Jane Andrews
OBJECTIVE: To review the outcomes of metastatic melanoma patients treated with infliximab for severe steroid-refractory colitis secondary to ipilimumab therapy. BACKGROUND: Immune-related colitis is a known potential adverse effect of ipilimumab, that causes significant morbidity and extended hospital stays. There are limited outcome data for patients treated with infliximab for ipilimumab-induced colitis refractory to corticosteroids. Management guidelines have been developed based on case study evidence only...
December 16, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27981753/association-between-genetic-polymorphisms-involved-in-the-hypoxia-inducible-factor-pathway-and-lung-cancer-risk-a-case-control-study-in-japan
#11
Yuzo Yamamoto, Chikako Kiyohara, Saiko Ogata-Suetsugu, Naoki Hamada, Yoichi Nakanishi
AIM: Hypoxia-inducible factor (HIF) contributes to the adaptation of tumor cells to hypoxic conditions, so genetic polymorphisms involved in this pathway may affect cellular response to hypoxia and be associated with cancer risk. Thus, we examined the association between the lung cancer risk and genetic polymorphisms involved in the HIF pathway. METHODS: This case-control study consists of 462 lung cancer cases and 379 controls from Japan. We examined the effect of HIF1A rs11549467, HIF1A rs11549465, HIF1A rs2057482, HIF2A rs13419896 and vascular endothelial growth factor A (VEGFA) rs833061 on the risk of lung cancer using TaqMan real-time PCR assay...
December 16, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27966288/an-analysis-of-incidental-and-symptomatic-pulmonary-embolism-pe-in-medical-oncology-patients
#12
D A Thaker, E Douglas, J Blazak, W Xu, B Hughes, M Burge, K Steinke, D Wyld
AIM: To determine the incidence of symptomatic versus incidental pulmonary embolism (PE) in oncology patients, characterize the nature and extent of incidental PE and the factors contributing to diagnosis. METHODS: Specialized web search engine was used to identify oncology patients with positive imaging studies for PE. PE identified at staging CT scans were classified as incidental PEs, whereas PE diagnosed by CTPA/VQ scan were classified as symptomatic PEs. RESULTS: A total of 111 patients with PE were identified over the period of three years...
December 14, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27885818/the-impact-of-bevacizumab-in-metastatic-colorectal-cancer-with-an-intact-primary-tumor-results-from-a-large-prospective-cohort-study
#13
Belinda Lee, Hui-Li Wong, Mark Tacey, Jeanne Tie, Rachel Wong, Margaret Lee, Louise Nott, Jeremy Shapiro, Ross Jennens, Natalie Turner, Ben Tran, Sumitra Ananda, Desmond Yip, Gary Richardson, Phillip Parente, Lionel Lim, Greg Stefanou, Matthew Burge, Mahesh Iddawela, Jeremy Power, Peter Gibbs
BACKGROUND: Debate continues regarding the benefits versus risks of initial resection of the primary tumor in metastatic colorectal cancer (mCRC) patients with an asymptomatic primary tumor. Although the benefit of the anti-vascular endothelial growth factor agent bevacizumab alongside first-line chemotherapy in mCRC is established, the impact of bevacizumab on the intact primary tumor (IPT) is less well understood. METHODS: Data from an Australian mCRC registry were used to assess the impact of bevacizumab-based regimens in the presence of an IPT, to see if this differs from effects in resected primary tumor (RPT) patients and to understand the safety profile of bevacizumab in patients with IPT...
November 25, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27869363/is-the-memorial-sloan-kettering-cancer-centre-mskcc-sarcoma-nomogram-useful-in-an-asian-population
#14
Deanna Wan Jie Ng, Grace Hwei Ching Tan, Claramae Shulyn Chia, Cindy Xindi Lim, Soo Khee Chee, Richard Hong Hui Quek, Mohamad Farid, Melissa Ching Ching Teo
AIM: A nomogram for prediction of 12-year sarcoma-specific survival has been developed based on patients with soft tissue sarcomas treated in Memorial Sloan Kettering Cancer Centre (MSKCC). We aim to evaluate the predictive accuracy of the MSKCC sarcoma nomogram in a cohort of patients treated at an Asian institution. This has not been validated in an Asian population and thus its universal applicability remains unproven. MATERIALS AND METHODS: Between 1990 and 2013, 840 adult patients underwent treatment for primary soft tissue sarcoma (STS) at the National Cancer Centre Singapore...
November 21, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27869361/clinical-outcomes-according-to-molecular-subtypes-in-stage-ii-iii-breast-cancer-patients-treated-with-neoadjuvant-chemotherapy-followed-by-surgery-and-radiotherapy
#15
Hakyoung Kim, Won Park, Seung Jae Huh, Doo Ho Choi, Jae Myoung Noh, Young-Hyuck Im, Jin Seok Ahn, Yeon Hee Park, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Eun Yoon Cho
AIM: We evaluated the tumor response and clinical outcomes according to molecular subtypes in stage II-III breast cancer patients who received neo-adjuvant chemotherapy (NAC) followed by surgery and radiotherapy. METHODS: We retrospectively analyzed 329 patients with clinical stage II-III breast cancer who received NAC followed by surgery and radiotherapy. Luminal A and B, HER2-enriched and triple-negative subgroups were identified. RESULTS: The overall pathologic complete response (pCR) rate after NAC was 20...
November 21, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27863058/the-living-well-after-breast-cancer%C3%A2-pilot-trial-a-weight-loss-intervention-for-women-following-treatment-for-breast-cancer
#16
Marina Reeves, Elisabeth Winkler, Nicole Mccarthy, Sheleigh Lawler, Caroline Terranova, Sandi Hayes, Monika Janda, Wendy Demark-Wahnefried, Elizabeth Eakin
AIM: Obesity is associated with poor prognosis and risk of treatment side-effects in breast cancer survivors. This pilot study assessed the feasibility, acceptability, safety and efficacy of a telephone-delivered weight loss intervention, among women (BMI 25-40 kg/m(2) ) following treatment for stage I-III breast cancer, on weight loss (primary outcome), quality of life and treatment-related side-effects (vs usual care). METHODS: Ninety women (mean ± SD age: 55...
November 10, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27863019/78gy-with-fiducial-marker-image-guided-radiotherapy-in-prostate-cancer-single-center-analysis-of-301-patients
#17
Ee Siang Choong, George Hruby, Jean Yang, Carol Kwong, Nitya Patanjali
AIM: In prostate cancer, fiducial marker image-guided radiotherapy (FMIGRT) allows correction of setup errors and interfraction physiological motion resulting in improved accuracy of target and sparing of at risk organs. We aim to report outcomes and toxicities observed in patients treated with dose escalation to 78Gy with FMIGRT in our center. METHODS AND MATERIALS: Retrospective review of consecutive patients with histologically confirmed T1-4N0M0 localized prostate cancer treated with dose escalation to 78Gy with FMIGRT in our center...
November 10, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27862983/denosumab-prevention-and-management-of-hypocalcemia-osteonecrosis-of-the-jaw-and-atypical-fractures
#18
REVIEW
Kenneth Pittman, Yoland C Antill, Amanda Goldrick, Jeffrey Goh, Richard H de Boer
Denosumab, a bone-modifying agent, reduces the risk of skeletal-related events in patients with bone metastases from solid tumors and is generally well tolerated. However, hypocalcemia, osteonecrosis of the jaw (ONJ) and atypical fracture are potential and important toxicities of denosumab therapy that require attention. In pivotal phase III trials in patients with bone metastases from solid tumors, the incidence of hypocalcemia was 9.6% in denosumab-treated patients, with most events being asymptomatic, grade 2 and resolving by week 4...
November 10, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27860270/systemic-treatment-in-advanced-biliary-cancers-a-multicenter-australian-analysis-and-review
#19
Daniel Brungs, Morteza Aghmesheh, Katrin Sjoquist, David Goldstein
AIM: While first-line palliative chemotherapy (CT1) improves survival and quality of life in advanced biliary cancer (ABC), there is no randomized evidence to support second-line chemotherapy (CT2) in ABC. We aim to explore to role of CT2 in ABC. METHODS: We performed a retrospective review of all patients who received one or more lines of chemotherapy for ABC at four Australian cancer centers between 2008 and 2011. A Cox proportional hazard model was developed to determine the impact of clinicopathologic variables on overall survival (OS) from time of progression on CT1...
November 10, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27813277/comparison-between-weekly-cisplatin-enhanced-radiotherapy-and-cetuximab-enhanced-radiotherapy-in-locally-advanced-head-and-neck-cancer-first-retrospective-study-in-asian-population
#20
Sheh Rawat, Parveen Ahlawat, Anjali Kakria, Gaurav Kumar, Ranga Rao Rangaraju, Abhishek Puri, Manoj Pal, Deepika Chauhan, Bharti Devnani, Pranav Chadha
AIM: To present a direct comparison between chemotherapy-enhanced radiotherapy (CERT) and biotherapy-enhanced radiotherapy (BERT) in locally advanced head and neck cancer. METHODS: It is a retrospective analysis of 53 patients with locally advanced head and neck cancer treated from August 2006 to December 2008. For CERT, patients received weekly cisplatin (40 mg/m(2) ) and for BERT, a loading dose of 400 mg/m(2) of cetuximab given one week prior to radiotherapy followed by 250 mg/m(2) given weekly along with radiotherapy...
November 3, 2016: Asia-Pacific Journal of Clinical Oncology
journal
journal
40999
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"